Background: Automated hematology analyzers are used to perform cell counts in body fluids. However, little is known about how the results compare between different analyzers.

Methods: A single batch of serous fluid samples was used to evaluate the cell counting performance of 3 hematology analyzers: CD 3700, XE 2100, and LH 750. Two hundred and seventy four serous fluid samples were used to evaluate the accuracy of the analyzers and to compare the results between different analyzers.

Results: The precision and linearity of the 3 analyzers were acceptable for both white blood cell counts and red blood cell counts with a low carryover rate. The limits of detection for white blood cells with the CD 3700, XE 2100, and LH 750 analyzers were 0.033×10(9)/l, 0.07×10(9)/l, and 0.20×10(9)/l, respectively. Performing background counts had no influence on cell counts for any of the analyzers. For those samples over the limit of detection, there was agreement between the automated and manual counting methods. There were also reasonably comparable cell count results between the 3 analyzers.

Conclusions: When the serous fluid cell counts are over the limit of detection, the analyzers produce accurate test results. Additionally, the results are comparable between the 3 hematology analyzers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2013.01.022DOI Listing

Publication Analysis

Top Keywords

cell counts
24
hematology analyzers
16
serous fluid
12
analyzers
9
automated hematology
8
cell
8
fluid samples
8
samples evaluate
8
3700 2100
8
2100 750
8

Similar Publications

Purpose: The incidence of cancer, which is a serious public health concern, is increasing. A predictive analysis driven by machine learning was integrated with haematology parameters to create a method for the simultaneous diagnosis of several malignancies at different stages.

Patients And Methods: We analysed a newly collected dataset from various hospitals in Jordan comprising 19,537 laboratory reports (6,280 cancer and 13,257 noncancer cases).

View Article and Find Full Text PDF

Whilst severe liver dysfunction is rarely encountered at the time of diagnosis for patients with acute myeloid leukemia (AML), mild elevations aminotransferase (<5 times the upper limit of normal) may be more frequently seen. Liver dysfunction at the time of diagnosis of AML is a parameter that requires investigation and can assist the clinicians in predicting prognosis. The aim of the present study was to investigate liver dysfunction at the time of diagnosis using the assoicated parameters in patients with AML.

View Article and Find Full Text PDF

Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy.

World J Gastrointest Oncol

January 2025

Department of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, Jiangsu Province, China.

Background: Owing to the absence of specific symptoms in early-stage gastric cancer, most patients are diagnosed at intermediate or advanced stages. As a result, treatment often shifts from surgery to other therapies, with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.

Aim: To investigate both treatment efficacy and immune modulation.

View Article and Find Full Text PDF

Acute myeloid leukaemia (AML) is a haematologic malignancy with high relapse rates in both adults and children. Leukaemic stem cells (LSCs) are central to leukaemopoiesis, treatment response and relapse and frequently associated with measurable residual disease (MRD). However, the dynamics of LSCs within the AML microenvironment is not fully understood.

View Article and Find Full Text PDF

Background: Mecapegfilgrastim, a long-acting granulocyte colony-stimulating factor, is approved in China for neutropenia prevention. However, data on its safety and efficacy in patients with head and neck cancer remain limited. This study aimed to evaluate the safety and efficacy of mecapegfilgrastim in preventing neutropenia among these patients undergoing chemotherapy, particularly those receiving chemoradiotherapy or chemoimmunotherapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!